Momenta To Pay $35M To Exit Blood Clot Drug Antitrust Suit

Law360 (December 11, 2019, 6:41 PM EST) -- Momenta has agreed to pay $35 million to exit a class action brought by a group of drug buyers accusing the company and Sandoz of conspiring to monopolize the blood clot drug Lovenox and its generic version.

According to a brief Tuesday filing with the U.S. Securities and Exchange Commission, Momenta said it has inked a $35 million settlement to release the company from the case, although further details about the proposed deal were not available beyond the payment schedule. Momenta said in the filing that such a settlement still would be subject to court approval, and added that the company...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!